Manchester, United Kingdom
Spectromics, a UK-based company founded in 2014, is revolutionizing the field of rapid antimicrobial susceptibility testing. Positioned at the intersection of biopharma, biotechnology, life sciences, and medical devices, Spectromics offers a pragmatic solution at the point-of-prescription.
Their offering is a simple yet advanced test aiding healthcare professionals in selecting the most effective treatment for infections within minutes, significantly reducing the traditional waiting period associated with microbiological cultures from days to minutes. By focusing on phenotypic testing, the company provides versatility in addressing varied microbial mutations.
The most recent financial boost for Spectromics came from their Series A investment on June 29, 2015. The round was led by prominent investors, MTI Ventures and New Wave Ventures. As they continue to hone their technology, Spectromics is well-positioned to address critical healthcare diagnostics needs globally.
